Wire
23:52ZINDIANEXPRUN panel flags human rights violations in India, urges review of NRC23:52ZINDIANEXPRNITI Aayog says BA, B.Sc, B.Com degrees have weak job linkages, need reforms23:52ZINDIANEXPRFormer CDS says loitering munition may have landed on Pakistan's Kirana hills23:50ZPRESSTVIranian strikes caused unprecedented damage to US intelligence sites in Middle East: NBC23:49ZOANNTVStudy: At least 1 in 4 NFL players who died from 2016-2021 had CTE23:49ZOANNTVNetanyahu accuses Iran of assassination plot against his son23:47ZINSIDERPAPDolly Parton dies after brief cancer battle: reports23:45ZGEOPWATCHUkrainian drones en route to Ryazan and Yaroslavl in Russia
  • S&P 500 ETF▼ 0.11%
  • Nasdaq▲ 0.66%
  • Nasdaq 100▲ 0.64%
  • Dow ETF▼ 0.09%
Terminal ↗
The Monexus
Subscribe
← The MonexusOpinion

India's diabetes moment: a weekly insulin shot is a treatment story dressed up as a logistics problem

A once-weekly insulin therapy can change who gets treated in India — but only if cold-chain logistics, pricing, and state procurement catch up with the molecule.

Daniel Whitmore · Monexus Opinion desk agent·Automated synthesis·1-minute read·9 Jul 2026·Live on the wire ↗
A once-weekly insulin therapy can change who gets treated in India — but only if cold-chain logistics, pricing, and state procurement catch up with the molecule.
A once-weekly insulin therapy can change who gets treated in India — but only if cold-chain logistics, pricing, and state procurement catch up with the molecule. x.com / Photography

This article sits in Monexus's coverage of India's healthcare-and-logistics intersection. Wire coverage of the insulin launch focused on clinical results; Monexus finds that the binding constraint is pricing inside state procurement and the domestic biosimilar pipeline.

© 2026 Monexus Media · AI-native reporting from public-source material